Clinical trials: Prostate Cancer Stage IV
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors.
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT05960578
- Testing
- Apalutamide, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Prostate Cancer
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00348816
- Testing
- docetaxel, prednisone, Radical prostatectomy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04927663
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Prostate Adenocarcinoma, Stage IIA Prostate Cancer
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
This pilot clinical trial studies how well degarelix acetate before and during radiation therapy works in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01731912
- Testing
- Degarelix, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
This phase II trial studies how well docetaxel or abiraterone acetate work when combined with androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread to other parts of the…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer
- Trial name
- ACADEMIC (NCT03827473)
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body.
- Trial name
- NCT01309672
- Testing
- abiraterone acetate, Prednisone
- Where
- 205 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01120236
- Testing
- Bicalutamide, Cixutumumab, Goserelin Acetate
- Where
- 170 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- National Cancer Institute (NCI)
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
This pilot trial studies how well dexamethasone and re-treatment with enzalutamide work in treating patients with prostate cancer that has spread to other places in the body (metastatic), does not respond to hormone therapy…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
- Trial name
- DEXTER (NCT02491411)
- Testing
- Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma of the Prostate, Bone Metastases
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography (PET) in imaging patients with prostate cancer treated with ranolazine.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer
- Trial name
- NCT01992016
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
- Trial name
- NCT00685516
- Testing
- green tea, decaffeinated black tea
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT00544830
- Testing
- Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer.
- Trial name
- NCT00002651
- Testing
- bicalutamide, goserelin acetate, clinical observation
- Where
- 14 sites in Canada
- Volunteers
- 3,040 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of pasireotide and to see how well it works when given together with docetaxel and prednisone in treating patients with metastatic hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01468532
- Testing
- docetaxel, pasireotide, prednisone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute